When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Venezuelan community in Lehigh Valley hopeful after Maduro’s capture while asking, what comes next? The Venezuelan community in the Lehigh Valley on Saturday celebrated the ouster of President ...
Pancreatic cancer is among the deadliest cancers. A new drug being tested at Penn is giving patients and doctors hope Former Major League Baseball star Lenny Dykstra was in possession of narcotics and ...
Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Phynart Studio / Getty Images A call option, ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
NIWOT — While Legacy's Matthew Clifton did what he believed he should have and dominated the 132-pound field at Niwot High School on Saturday, Frederick's Dominick Abeyta is learning just how far a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback